Trial Profile
Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Autistic disorder
- Focus Proof of concept; Therapeutic Use
- 23 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 07 Feb 2015 New trial record